US2012128703A1PendingUtilityA1
Aminopterin Dosage Forms and Methods for Inflammatory Disorders
Individually held — no corporate assignee on recordPriority: Mar 11, 2005Filed: Jan 29, 2012Published: May 24, 2012
Est. expiryMar 11, 2025(expired)· nominal 20-yr term from priority
A61P 37/00A61P 43/00A61P 37/08A61P 37/06A61P 29/00A61P 17/02A61P 17/06A61K 31/519A61P 11/00A61P 1/04A61P 19/02A61K 31/525
56
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
There is disclosed dosage forms and methods for treating a patient with an inflammatory disorder with a therapeutically effective amount of aminopterin, or a pharmaceutically acceptable salt thereof, that achieve efficacy without concomitant toxicity. Specifically, there is disclosed a method for treating an inflammatory disorder in a patient with uninterrupted doses of aminopterin.
Claims
exact text as granted — not AI-modified1 - 16 . (canceled)
17 . A method for treating systemic lupus erythematosus, graft-versus-host-disease (GVHD) and polymyositis comprising administering an effective amount of aminopterin or a pharmaceutically acceptable salt thereof.
18 . The method for treating systemic lupus erythematosus, graft-versus-host-disease and polymyositis of claim 17 wherein the therapeutically effective amount of aminopterin is not greater than 0.07 mg aminopterin per kilogram of patient body weight.Join the waitlist — get patent alerts
Track US2012128703A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.